Skip to main content

Disparities Seen in Cancer Treatment Delivery at Minority-Serving Hospitals

Medically reviewed by Carmen Pope, BPharm. Last updated on May 28, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, May 28, 2024 -- There are systemic disparities in definitive cancer treatment delivery at minority-serving hospitals (MSHs) versus non-MSHs, according to a study published online May 27 in Cancer.

Edoardo Beatrici, M.D., from Brigham and Women's Hospital in Boston, and colleagues used data from the National Cancer Database for 2010 to 2019 to examine patients who were eligible for definitive treatments for breast, prostate, non-small cell lung, and colon cancer. MSHs were classified as hospitals in the top decile by minority patient proportion. The odds of receiving definitive treatment were compared at MSHs versus non-MSHs.

The researchers found that 9.3 percent of 2,927,191 patients from 1,330 hospitals were treated at MSHs. Across all cancer types, significantly lower odds of delivering definitive therapy were seen at MSHs (adjusted odds ratios, 0.83, 0.69, 0.73, and 0.81 for breast cancer, prostate cancer, non-small cell lung cancer, and colon cancer, respectively). No significant site of care-race interaction was seen for any of the cancers. A total of 5,719 additional patients receiving definitive treatment over 10 years could result from equalizing treatment rates at MSHs.

"To truly achieve health care equity, our results underscore the importance of system‐wide efforts that integrate improvements at MSHs with broader strategies aimed at eliminating these disparities," the authors write. "Enhancing care at MSHs is a key step within a larger framework of initiatives designed to ensure equitable health care outcomes for all."

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Vaginal Cancer Incidence Increasing Globally

WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.